跳至主要内容
临床试验/NCT04192409
NCT04192409已完成不适用

Glycemic Control Using Mobile-based Intervention in Patients With Diabetes Undergoing Coronary Artery Bypass to Promote Self-management

China National Center for Cardiovascular Diseases1 个研究点 分布在 1 个国家目标入组 1,038 人开始时间: 2020年1月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
1,038
试验地点
1
主要终点
Change in glucose level measured by HbA1C level

研究概览

简要总结

The study is a two-arm parallel, randomized clinical trial. The purpose of the study is to evaluate the effectiveness and feasibility of using high-quality medication reminder smartphone application as a tool for secondary prevention in patients undergone CABG with DM, including the change in quality of life, medication adherence improvement and clinical outcome. The participants will be randomized into intervention and control groups in a 1:1 ratio. The intervention group will receive information of secondary prevention of CHD and medication alarm using a specific smartphone application, while the control group will receive usual care.

详细描述

Objective

this study designed to evaluate the effectiveness and feasibility of using high-quality medication reminder smartphone application as a tool for secondary prevention in patients undergone CABG with DM, including the change in quality of life, medication adherence improvement and clinical outcome.

Study design: the study is a two-arm, parallel, randomized clinical trial. Patients will be eligible if they have undergone CABG at this admission, have a history of diabetes mellitus, have the capability of reading and using smartphone application, and are able to provide informed consent. Patients will be excluded if they do not have smartphone. The eligible participants will be allocated into intervention and control groups in a 1:1 ratio randomly. The intervention group will receive intervention of smartphone application in addition to usual care, while the control group will receive usual care. All the participants will be followed up for 6 months.

Study intervention: participants in the intervention group will install a specific costume smartphone application, which will send health education information, medication alarm and risk factor questionnaire at a fixed frequency to aid patients' self-evaluation, recording patients' recent fast plasma glucose value in addition to usual care.

Outcome measures: The primary endpoint is the change in glycemic hemoglobin (HbA1C). Secondary endpoints include MACCE, medication adherence, quality of life and status of graft vessel.

Statistical analysis

Evaluation will be carried out on an intention-to-treat basis. Values of analyzed endpoints between intervention group and control group will be compared according to the analysis plan. We'll follow a prespecified analysis plan and subgroup analysis will be conducted accordingly.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Supportive Care
盲法
None

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Diagnose with type 2 diabetes before this administration;
  • Postoperative patients undergoing CABG in this hospitalization;

排除标准

  • Die before discharge;
  • Disability of reading, vision or hearing which leads to disability of using smartphone;
  • Cognitive communication impairments or communication disorder;
  • Unable to use smartphone.

结局指标

主要结局

Change in glucose level measured by HbA1C level

时间窗: Baseline; 6 months

We will measured the change in glucose level from baseline to 6 months.

次要结局

  • blood pressure(6 months)
  • The incidence of all-cause death(6 months)
  • Medication adherence(6 months)
  • EQ-5D(6 months)
  • Status of the graft vessels(6 months)
  • The incidence of major adverse cardiovascular events(MACE)(6 months)
  • blood glucose(6 months)
  • low density lipoprotein(6 months)

研究者

发起方
China National Center for Cardiovascular Diseases
申办方类型
Other Gov
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验